Life sciences stocks continued an upward trajectory at the end of 2020, with median gains of at least 7% in 4Q20 and at least 24% over the year across all market cap tiers. Companies valued...

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...

Several inflammatory and cancer indications will soon see human proof-of-concept data from small molecules targeting the kinase IRAK4, as a class of at least eight such molecules makes its way through early-stage trials. IRAK4 mediates innate...

Cardior plans to build on early clinical data for its antisense oligonucleotide in heart failure patients by moving the RNA therapy into niche indications where it believes the product can help dysfunctional...

Amgen readies sotorasib for FDA  Amgen Inc. (NASDAQ:AMGN) said it plans to submit an NDA for its closely watched KRAS inhibitor sotorasib by year-end to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C...

DISEASE CATEGORY: Musculoskeletal; ophthalmic disease INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has designed an RNA-targeting small molecule that could treat DM1 and Fuchs...

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...

In the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s liquid biopsy test, growing the number of genetic biomarkers indicated for matching patients to targeted therapies. The...

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the tumor microenvironment. In patients with glioblastoma multiforme, high expression of...

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy Antisense oligonucleotide therapies targeting DUX4 could treat facioscapulohumeral muscular dystrophy (FSHD), which is caused by aberrant expression of the transcription factor. Screening of seven locked nucleic acid (LNA) gapmer...